1138018-25-3

Basic information

• Product Name: Benzyl N,N-bis(tert-butoxycarbonyl)-5-oxo-L-norvalinate
• Synonyms: Benzyl N,N-bis(tert-butoxycarbonyl)-5-oxo-L-norvalinate;MTIFZHHXZBCEMJ-KRWDZBQOSA-N
• CAS NO: 1138018-25-3
• Molecular Formula: C₂₂H₃₁NO₇
• Molecular Weight: 421.48404
• Mol File: 1138018-25-3.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzyl N,N-bis(tert-butoxycarbonyl)-5-oxo-L-norvalinate(CAS DataBase Reference)
• NIST Chemistry Reference: Benzyl N,N-bis(tert-butoxycarbonyl)-5-oxo-L-norvalinate(1138018-25-3)
• EPA Substance Registry System: Benzyl N,N-bis(tert-butoxycarbonyl)-5-oxo-L-norvalinate(1138018-25-3)

Safety Data

• Hazardous Substances Data: 1138018-25-3(Hazardous Substances Data)

Upstream product

• 132245-78-4 (S)-2-tert-butoxycarbonylaminopentanedioic acid 1-benzyl ester 5-methyl ester 
• 30924-93-7 Boc-Glu-OBn 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1138018-24-2 (S)-1-benzyl 5-methyl 2-(bis((tert-butoxy)carbonylamino))pentanedioate 

Downstream Products

• 1310077-22-5 benzyl 2-(S)-[bis-(tert-butoxycarbonyl)amino]-5-hexenoate 
• 1370623-34-9 (S,E)-7-benzyl 1-(tert-butyl) 6-(bis((tert-butoxy)carbonylamino))hept-2-enedioate 
• 1207285-00-4 C₃₈H₄₅FN₄O₁₁ 

Relevant articles and documents

METHOD FOR PRODUCING DESMOSINE, ISODESMOSINE AND DERIVATIVES THEREOF

A process for preparing a compound represented by the following general formula (I) or a salt thereof, which comprises reacting lysine or a protective product thereof or a salt thereof with allysine or a protective product thereof in the presence of a spe

Development of a solid-phase approach to the natural product class of Ahp-containing cyclodepsipeptides

The 3-amino-6-hydroxy-2-piperidone (Ahp) containing cyclodepsipeptides are an interesting class of natural products that inhibit S1 (trypsin and chymotrypsin-like) serine protease in a reversible, noncovalent manner, turning them into potential chemical t

C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS

The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.